ELV — Elevance Health Inc.

Elevance Health Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Diluted EPS: $12.58, exceeding expectations.
• Operating Revenue: $49.5 billion, up 1.5% year-over-year.
• Membership: 45.4 million members, an increase of nearly 200,000 from year-end.
• Benefit Expense Ratio: 86.8%.
• Operating Expense Ratio: 10.5%, improved by 20 basis points year-over-year.
• Operating Cash Flow: $4.3 billion, with a full-year expectation of at least $5.5 billion.
• Share Repurchases: 3.7 million shares for $1.1 billion at an average price of over $300 per share.

2. Strategic Updates and Business Highlights

• Leadership Realignment: Strengthened coordination between health benefits and Carelon to enhance execution.
• AI Integration: Scaling AI across clinical and operational workflows, leading to improved member engagement and cost management.
• Carelon Transformation: Integrated CareBridge and home care capabilities into a single risk-based solution, achieving a 20% reduction in hospital readmissions and over 10% savings on post-acute care.
• Medicaid Initiatives: Early evidence of cost reductions in behavioral health and specialty pharmacy through targeted interventions.
• Medicare Advantage: Improved performance driven by product repositioning, on track for at least a 2% operating margin in 2026.
• Commercial Business: Maintained disciplined pricing, with strong employer interest and a robust pipeline for 2027.

3. Forward Guidance and Outlook

• Adjusted EPS Guidance: Raised to at least $26.75 for 2026, with expectations of at least 12% adjusted EPS growth in 2027.
• Medicaid Membership: Anticipated high single-digit percentage decline due to eligibility reverifications, with expectations to finish towards the higher end of that range.
• Carelon's Role: Expected to continue driving performance and long-term growth.

4. Bad News, Challenges, or Points of Concern

• CMS Risk Adjustment Data: Received a notice from CMS regarding historical data, leading to a $935 million accrual for potential exposure, although management remains confident in the integrity of current practices.
• Medicaid Margin Pressure: Operating margin guidance for Medicaid remains at approximately -1.75%, with ongoing discussions for rate adjustments with states.
• Membership Mix Concerns: Potential pressure on risk pools due to membership declines among lower-utilizing members, particularly in Medicaid.

5. Notable Q&A Insights

• Commercial Selling Season: Strong early interest from employers focused on affordability and experience, with a record pipeline for 2027.
• Cost Trends: Cost trends are tracking in line with expectations, with proactive measures showing early benefits in managing claims.
• AI and Automation: Investments in AI are aimed at reducing costs and improving member experience, with significant early adoption and positive results in operational efficiency.
• Carelon's Performance: Continued investment in Carelon services is expected to enhance margins over time, despite current pressures from lower health plan membership.
• Regulatory Environment: Ongoing federal actions on PBM transparency are seen as aligning with Elevance's business model, which focuses on integrated medical and pharmacy management.

Overall, Elevance Health reported a strong start to 2026 with positive financial results and strategic initiatives aimed at improving efficiency and member engagement, while also navigating challenges in Medicaid and regulatory environments.